| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 19,552 | 21,762 | 40,795 | 44,969 |
| Product | 6,728 | 7,608 | - | - |
| Services And Other Revenue | 3,340 | 3,526 | - | - |
| Total cost of revenue | 10,068 | 11,134 | 21,054 | 21,708 |
| Gross profit | 9,484 | 10,628 | 19,741 | 23,261 |
| Research and development | 6,356 | 6,222 | 11,328 | 13,156 |
| Selling, general and administrative | 26,595 | 28,105 | 38,707 | 34,403 |
| Restructuring and related charges | 9,428 | 1,727 | 1,552 | 2,341 |
| Transaction and integration expenses | 43 | 271 | 1,124 | 5,079 |
| Total operating expenses | 42,422 | 36,325 | 52,711 | 54,979 |
| Loss from continuing operations | -32,938 | -25,697 | -32,970 | -31,718 |
| Bargain purchase gain | 0 | 0 | - | - |
| Interest income | 2,140 | 2,461 | 2,916 | 3,941 |
| Interest expense | 10 | 9 | 2 | - |
| Other income (expense), net | -2,092 | 4,963 | 3,872 | 957 |
| Loss from continuing operations before income taxes | -32,900 | -18,282 | -26,184 | -26,820 |
| Income tax benefit (expense) | -1,216 | -609 | -151 | 118 |
| Net loss from continuing operations | -31,684 | -17,673 | - | - |
| Revenue | 26,693 | - | - | - |
| Cost of revenue | 14,352 | - | - | - |
| Gross profit | 12,341 | - | - | - |
| Selling, general and administrative expenses | 8,474 | - | - | - |
| Research and development | 4,849 | - | - | - |
| Transaction expenses | 2,203 | - | - | - |
| Other (income) expense, net | -181 | - | - | - |
| Total operating expenses | 15,345 | - | - | - |
| Loss from discontinued operations before income taxes | -3,004 | - | - | - |
| Income tax benefit (expense) | -1 | - | - | - |
| Loss from discontinued operations, net of tax | -3,003 | -15,786 | - | - |
| Net loss | -34,687 | -33,459 | -26,033 | -26,938 |
| Induced conversion of redeemable preferred stock | 0 | 0 | - | - |
| Net loss attributable to common stockholders | -34,687 | -33,459 | - | - |
| Earnings per share, basic | -0.09 | -0.09 | -0.07 | -0.07 |
| Earnings per share, diluted | -0.09 | -0.09 | -0.07 | -0.07 |
| Weighted average number of shares outstanding, basic, total | 382,630,000 | 380,498,000 | 378,228,000 | 371,538,000 |
| Weighted average number of shares outstanding, diluted, total | 382,630,000 | 380,498,000 | 378,228,000 | 371,538,000 |
STANDARD BIOTOOLS INC. (LAB)
STANDARD BIOTOOLS INC. (LAB)